Please login to the form below

Not currently logged in
Email:
Password:

Greenleaf Health appoints drug and biological products principal

Dr John Jenkins joins the FDA regulatory consulting firm

Washington, US-based Greenleaf Health has appointed Dr John Jenkins as principal for drug and biological products.

Dr Jenkins brings over 25 years of experience from the US Food and Drug Administration (FDA) to the regulatory consulting firm, and is set to oversee its clients' drug development programmes through regulatory submission and post-approval requirements.

Most recently, he served as director of the office of new drugs within the FDA's Center for Drug Evaluation and Research. He previously held several leadership positions at the regulatory body, including director of the office of drug evaluation and director of the division of pulmonary drug products.

Patrick Ronan, chief executive of Greenleaf Health, said: “No one is more qualified than John to provide our clients strategic and technical guidance on FDA's regulatory process for drug and biological product development.

“Our experts at Greenleaf, who have a combined total of more than 200 years of FDA experience, help our clients navigate complex regulatory challenges. John's knowledge and experience in this area are unrivaled, and he makes a great addition to our team.”

20th February 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics